ArticleBritish journal of cancer2006
Desmocollin switching in colorectal cancer.
Article in British journal of cancer, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 92 citations in OpenAlex.
- M2 macrophage associated genes shape prognosis and tumor progression in human colorectal cancer.iScience · 2026Article
- Desmosome mutations impact the tumor microenvironment to promote melanoma proliferation.Nature genetics · 2025Article
- MicroRNA-32-5p promotes the proliferation and metastasis of gastric cancer cells.Scientific reports · 2025Article
- Desmosome mutations impact the tumor microenvironment to promote melanoma proliferation.bioRxiv : the preprint server for biology · 2024Article
- A complex of cadherin 17 with desmocollin 1 and p120-catenin regulates colorectal cancer migration and invasion according to the cell phenotype.Journal of experimental & clinical cancer research : CR · 2024Article
- A transcriptome study of p53-pathway related prognostic gene signature set in bladder cancer.Heliyon · 2023Article
- Desmocollin-1 is associated with pro-metastatic phenotype of luminal A breast cancer cells and is modulated by parthenolide.Cellular & molecular biology letters · 2023Article
- Article
- Article
- Role of Cell-Cell Junctions in Oesophageal Squamous Cell Carcinoma.Biomolecules · 2022Review
- Weighted correlation network analysis revealed novel long non-coding RNAs for colorectal cancer.Scientific reports · 2022Article
- Desmosomal Cadherins in Health and Disease.Annual review of pathology · 2022Review
- DSC2 Suppresses the Metastasis of Gastric Cancer through Inhibiting the BRD4/Snail Signaling Pathway and the Transcriptional Activity ofOxidative medicine and cellular longevity · 2022Article
- Verification and Validation of a Four-Gene Panel as a Prognostic Indicator in Triple Negative Breast Cancer.Frontiers in oncology · 2022Article
- Genetic Factors Involved in Cardiomyopathies and in Cancer.Journal of clinical medicine · 2020Review
- The Construction and Analysis of Tumor-Infiltrating Immune Cells and ceRNA Networks in Bladder Cancer.Frontiers in genetics · 2020Article
- MLS128 antibody-induced suppression of colon cancer cell growth is mediated by a desmocollin and a 110 kDa glycoprotein.Bioscience trends · 2019Article
- Review
- EnteropathogenicCellular and molecular gastroenterology and hepatology · 2018Article
- Stat3 regulates desmoglein 3 transcription in epithelial keratinocytes.JCI insight · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
The desmocollins are members of the desmosomal cadherin family of cell-cell adhesion molecules. They are essential constituents of desmosomes, intercellular junctions that play a critical role in the maintenance of tissue integrity in epithelia and cardiac muscle. In humans, three desmocollins (Dsc1, Dsc2 and Dsc3) have been described. The desmocollins exhibit tissue-specific patterns of expression; only Dsc2 is expressed in normal colonic epithelium. We have found switching between desmocollins in sporadic colorectal adenocarcinoma with a reduction in Dsc2 protein (in 8/16 samples analysed by immunohistochemistry) being accompanied by de novo expression of Dsc1 (16/16) and Dsc3 (7/16). Similar results were obtained by western blotting of a further 16 samples. No change was found in Dsc2 mRNA, but de novo expression of Dscs 1 and 3 was accompanied by increased message levels. Loss of Dsc2 (8/19) and de novo expression of Dsc1 (11/19) and Dsc3 (6/19) was also found in colorectal adenocarcinomas on a background of colitis. The data raise the possibility that switching of desmocollins could play an important role in the development of colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.